Gilead Sciences, Inc. (NASDAQ:GILD) reported data from two Phase 2 studies and a compassionate access study, wherin a regimen containing once-daily Sovaldi 400 mg was administered to treat chronic hepatitis C virus or HCV infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $70.80 moved to $71.23 on last trade day and at the end of the day closed at $65.48. Company price to sales ratio in past twelve months was calculated as 8.99 and price to cash ratio as 47.24. Gilead Sciences, Inc. (NASDAQ:GILD) showed a negative weekly performance of -11.51%.
Shares of drug maker MannKind (NASDAQ:MNKD) are falling after a potential competitor, Dance Biopharm, sought to launch an initial public offering. MannKind Corporation (NASDAQ:MNKD) shares fell -2.14% in last trading session and ended the day on $6.85. MNKD return on equity ratio is recorded as 153.90% and its return on assets is -78.70%. MannKind Corporation (NASDAQ:MNKD) yearly performance is 59.67%.
Ariad Pharmaceuticals (NASDAQ:ARIA) VP Daniel Bollag unloaded 2,400 shares of the stock on the open market in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $8.22, for a total transaction of $19,728.00. Following the sale, the vice president now directly owns 148,063 shares of the company’s stock, valued at approximately $1,217,078. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -4.74% in last trading session and was closed at $7.23, while trading in range of $7.12 – $7.64. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is 6.01%.
From being a newbie on the Pharmaceutical block to becoming top hitter on various investor’s list, Inovio Pharmaceuticals (NYSE:INO) gained its first momentum at an initial stage by getting recognition form the World Vaccine Congress. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) weekly performance is -9.91%. On last trading day company shares ended up $3.00. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -5.83%. Analysts mean target price for the company is $4.60.
Leave a Reply